Injection site pain; Injection site swelling; Swelling in glands of armpit; Pain in glands of armpit; Sever headache; Severe migrane; Severe nausea; Muscle spasm in legs; Fever of 103; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of injection site pain in a 48-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2022-2023 season) for prophylaxis.   Co-suspect products included TOZINAMERAN (COVID-19 VACCINE PFIZER) (batch number FP7136) for prophylaxis.   Concurrent medical conditions included drug allergy (ancef).   On 24-MAR-2023, the patient received Fluarix Quadrivalent 2022-2023 season (left arm) and the 2nd dose of COVID-19 VACCINE PFIZER (left arm). On 25-MAR-2023, 1 days after receiving Fluarix Quadrivalent 2022-2023 season, the patient experienced injection site pain (Verbatim: Injection site pain), injection site swelling (Verbatim: Injection site swelling), swollen glands (Verbatim: Swelling in glands of armpit), axillary pain (Verbatim: Pain in glands of armpit), headache (Verbatim: Sever headache), migraine (Verbatim: Severe migrane), nausea (Verbatim: Severe nausea), leg spasm (Verbatim: Muscle spasm in legs) and fever (Verbatim: Fever of 103). The outcome of the injection site pain, injection site swelling, swollen glands, axillary pain, headache, migraine, nausea, leg spasm and fever were not resolved.   It was unknown if the reporter considered the injection site pain, injection site swelling, swollen glands, axillary pain, headache, migraine, nausea, leg spasm and fever to be related to Fluarix Quadrivalent 2022-2023 season and Fluarix Tetra Pre-Filled Syringe Device.     It was unknown if the company considered the injection site pain, injection site swelling, swollen glands, axillary pain, headache, migraine, nausea, leg spasm and fever to be related to Fluarix Quadrivalent 2022-2023 season and Fluarix Tetra Pre-Filled Syringe Device.   This report is made without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: Receipt Date: 28-MAR-2023 On 2 Mar 2023, the patient received pfizer drug Dose Number 1, Batch No FP7136 Location of injection Left Arm. On 24th March 2023, the patient received Fluarix Quad 2022-2023 and Pfizer covid19 vaccine. On 25th March 2023, the patient experienced pain and swelling at injection site and in gland of armpit, severe headache and migraine, severe nausea, muscle spasms in legs and fever of 103 which was not recovered at the time of reporting. The lot number for Pfizer covid19 vaccine was reported as FP7136. On 25th March 2023, the patient had negative nasal swab test. The patient had a drug allergy for Ancef. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received any other medications the patient received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID 19. It was unknown if the reporter considered the injection site pain, injection site swelling, swollen glands, axillary pain, headache, migraine, nausea, leg spasm and fever to be related to COVID 19 vaccine. The reporter consented to follow up.